Participant must be 2 to \< 18 years of age at the time of signing the informed consent or assent.
Stable and maximum allowed or tolerated RAASI (ACEI and/or ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106.
UPCR ≥ 1.0 g/g from the mean of 3 first morning voids (FMV) collected within 1 week during the Screening Period
Estimated GFR ≥ 30 mL/min/1.73 m2 during Screening
Meningococcal infection vaccine
Haemophilus influenzae type b and Streptococcus pneumoniae vaccine
Participants who are receiving SGLT2i, DEARA (eg, sparsentan), MRA, ERA, or GLP-1 agonists must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change in dose through Week 34.
Established diagnosis of primary IgAN diagnosis based on kidney biopsy within 3 years prior to Screening or during the Screening Period
You may not be if
Diagnosis of rapidly progressive glomerulonephritis
Secondary forms of IgAN not in the context of primary IgAN or IgAV
Concomitant clinically significant renal disease other than IgAN or IgAVN
Clinical remission of IgAN/IgAVN or clinically significant improvement in proteinuria within the last 6 months.
Uncontrolled diabetes mellitus with HbA1c \> 8.5%
History of kidney transplant or planned kidney transplant during the Primary Evaluation Period.
History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant
Splenectomy or functional asplenia
Participants with nephrotic syndrome receiving albumin infusions or with acute kidney injury requiring dialysis within the last 6 months prior to Screening.
Hemolytic uremic syndrome diagnosed any time prior to Screening.
Planned urological surgery expected to influence kidney function within the study time frame.
Congenital immunodeficiency
Active systemic bacterial, viral, or fungal infection within 14 days prior to enrollment
Received biologics for the treatment of IgAN or IgAVN within≤ 6 months prior to Screening
Clareo Health | Study of Ravulizumab in Pediatric Participants With Primary IgAN
